• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

异质性的复杂本质及其在乳腺癌生物学和治疗反应中的作用。

The complex nature of heterogeneity and its roles in breast cancer biology and therapeutic responsiveness.

机构信息

The Hormel Institute, University of Minnesota, Austin, MN, United States.

Department of Biochemistry and Pharmacology, Universidade Federal do Piaui, Piauí, Brazil.

出版信息

Front Endocrinol (Lausanne). 2023 Feb 23;14:1083048. doi: 10.3389/fendo.2023.1083048. eCollection 2023.

DOI:10.3389/fendo.2023.1083048
PMID:36909339
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9997040/
Abstract

Heterogeneity is a complex feature of cells and tissues with many interacting components. Depending on the nature of the research context, interacting features of cellular, drug response, genetic, molecular, spatial, temporal, and vascular heterogeneity may be present. We describe the various forms of heterogeneity with examples of their interactions and how they play a role in affecting cellular phenotype and drug responses in breast cancer. While cellular heterogeneity may be the most widely described and invoked, many forms of heterogeneity are evident within the tumor microenvironment and affect responses to the endocrine and cytotoxic drugs widely used in standard clinical care. Drug response heterogeneity is a critical determinant of clinical response and curative potential and also is multifaceted when encountered. The interactive nature of some forms of heterogeneity is readily apparent. For example, the process of metastasis has the properties of both temporal and spatial heterogeneity within the host, whereas each individual metastatic deposit may exhibit cellular, genetic, molecular, and vascular heterogeneity. This review describes the many forms of heterogeneity, their integrated activities, and offers some insights into how heterogeneity may be understood and studied in the future.

摘要

异质性是细胞和组织的一个复杂特征,具有许多相互作用的组成部分。根据研究背景的性质,细胞、药物反应、遗传、分子、空间、时间和血管异质性的相互作用特征可能存在。我们描述了各种形式的异质性,并举例说明了它们的相互作用以及它们如何在影响乳腺癌细胞表型和药物反应方面发挥作用。虽然细胞异质性可能是最广泛描述和引用的,但肿瘤微环境中存在许多形式的异质性,它们会影响内分泌和细胞毒性药物在标准临床护理中的反应。药物反应异质性是临床反应和治疗潜力的关键决定因素,而且在遇到时也是多方面的。一些形式的异质性的相互作用性质是显而易见的。例如,转移过程在宿主内具有时间和空间异质性的特性,而每个单独的转移沉积物可能表现出细胞、遗传、分子和血管异质性。这篇综述描述了许多形式的异质性、它们的综合活动,并提供了一些关于如何在未来理解和研究异质性的见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b045/9997040/4f77629560fd/fendo-14-1083048-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b045/9997040/e957ce662910/fendo-14-1083048-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b045/9997040/4f77629560fd/fendo-14-1083048-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b045/9997040/e957ce662910/fendo-14-1083048-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b045/9997040/4f77629560fd/fendo-14-1083048-g002.jpg

相似文献

1
The complex nature of heterogeneity and its roles in breast cancer biology and therapeutic responsiveness.异质性的复杂本质及其在乳腺癌生物学和治疗反应中的作用。
Front Endocrinol (Lausanne). 2023 Feb 23;14:1083048. doi: 10.3389/fendo.2023.1083048. eCollection 2023.
2
Quantitative Clinical Imaging Methods for Monitoring Intratumoral Evolution.用于监测肿瘤内演变的定量临床成像方法
Methods Mol Biol. 2017;1513:61-81. doi: 10.1007/978-1-4939-6539-7_6.
3
Heterogeneity of breast cancer: The importance of interaction between different tumor cell populations.乳腺癌的异质性:不同肿瘤细胞群体相互作用的重要性。
Life Sci. 2019 Dec 15;239:117009. doi: 10.1016/j.lfs.2019.117009. Epub 2019 Oct 24.
4
The multi-factorial nature of clinical multidrug resistance in cancer.癌症临床多药耐药性的多因素性质。
Drug Resist Updat. 2019 Sep;46:100645. doi: 10.1016/j.drup.2019.100645. Epub 2019 Sep 17.
5
Taking a Full Snapshot of Cancer Biology: Deciphering the Tumor Microenvironment for Effective Cancer Therapy in the Oncology Clinic.全面剖析癌症生物学:解析肿瘤微环境,以实现肿瘤学临床的有效癌症治疗。
OMICS. 2020 Apr;24(4):175-179. doi: 10.1089/omi.2020.0019. Epub 2020 Mar 13.
6
Microenvironment and autophagy cross-talk: Implications in cancer therapy.微环境与自噬相互作用:在癌症治疗中的意义。
Pharmacol Res. 2016 May;107:300-307. doi: 10.1016/j.phrs.2016.03.031. Epub 2016 Mar 29.
7
Not Everyone Fits the Mold: Intratumor and Intertumor Heterogeneity and Innovative Cancer Drug Design and Development.并非人人都符合模式:肿瘤内和肿瘤间异质性以及创新型癌症药物设计和开发。
OMICS. 2018 Jan;22(1):17-34. doi: 10.1089/omi.2017.0174.
8
Macrophage Flipping from Foe to Friend: A Matter of Interest in Breast Carcinoma Heterogeneity Driving Drug Resistance.巨噬细胞从敌人到朋友的转变:乳腺癌异质性驱动耐药性中的利益问题。
Curr Cancer Drug Targets. 2019;19(3):189-198. doi: 10.2174/1568009618666180628102247.
9
Metabolic reprogramming: the emerging concept and associated therapeutic strategies.代谢重编程:新兴概念及相关治疗策略
J Exp Clin Cancer Res. 2015 Oct 6;34:111. doi: 10.1186/s13046-015-0221-y.
10
Why Tumor Genetic Heterogeneity May Require Rethinking Cancer Genesis and Treatment.为什么肿瘤遗传异质性可能需要重新思考癌症的发生和治疗。
Trends Cancer. 2021 May;7(5):400-409. doi: 10.1016/j.trecan.2020.10.013. Epub 2020 Nov 23.

引用本文的文献

1
Therapeutic evaluation of paclitaxel co-loaded PLGA nanoparticles with imatinib, protamine-imatinib, and gefitinib: comparative in vitro studies in MDA-MB-231 breast cancer cells and in vivo investigations in rats.载有紫杉醇的聚乳酸-羟基乙酸共聚物纳米粒与伊马替尼、鱼精蛋白-伊马替尼和吉非替尼的治疗评估:在MDA-MB-231乳腺癌细胞中的体外比较研究及在大鼠中的体内研究
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jul 18. doi: 10.1007/s00210-025-04460-w.
2
FGFR1 overexpression promotes resistance to PI3K inhibitor alpelisib in luminal breast cancer cells through receptor tyrosine kinase signaling-mediated activation of the estrogen receptor.FGFR1过表达通过受体酪氨酸激酶信号介导的雌激素受体激活,促进腔面型乳腺癌细胞对PI3K抑制剂阿培利司产生耐药性。
Cancer Drug Resist. 2025 May 28;8:24. doi: 10.20517/cdr.2024.181. eCollection 2025.
3

本文引用的文献

1
Therapy sculpts the complex interplay between cancer and the immune system during tumour evolution.治疗在肿瘤进化过程中塑造了癌症和免疫系统之间的复杂相互作用。
Genome Med. 2022 Dec 7;14(1):137. doi: 10.1186/s13073-022-01138-3.
2
Single cell metabolism: current and future trends.单细胞代谢:当前和未来的趋势。
Metabolomics. 2022 Oct 1;18(10):77. doi: 10.1007/s11306-022-01934-3.
3
The role of hypoxia-inducible factor-1 alpha in multidrug-resistant breast cancer.缺氧诱导因子-1α在多药耐药乳腺癌中的作用
The predictive value of HER2DX assay with pathological response and prognosis in patients with early HER2-positive breast cancers: commentary on the PHERGain trial.HER2DX检测对早期HER2阳性乳腺癌患者病理反应和预后的预测价值:对PHERGain试验的评论
Transl Cancer Res. 2025 Mar 30;14(3):1507-1510. doi: 10.21037/tcr-2024-2421. Epub 2025 Mar 20.
4
From silent partners to potential therapeutic targets: macrophages in colorectal cancer.从沉默伙伴到潜在治疗靶点:结直肠癌中的巨噬细胞
Cancer Immunol Immunother. 2025 Feb 25;74(4):121. doi: 10.1007/s00262-025-03965-w.
5
Case report: Bone marrow metastasis and bone marrow necrosis occurring 11 years after ductal carcinoma of the breast.病例报告:乳腺癌导管癌发生11年后出现骨髓转移和骨髓坏死。
Front Oncol. 2024 Dec 23;14:1473896. doi: 10.3389/fonc.2024.1473896. eCollection 2024.
6
Exosomes and breast cancer angiogenesis; Highlights in intercellular communication.外泌体与乳腺癌血管生成;细胞间通讯要点
Cancer Cell Int. 2024 Dec 18;24(1):402. doi: 10.1186/s12935-024-03606-9.
7
Applicability of Quantum Dots in Breast Cancer Diagnostic and Therapeutic Modalities-A State-of-the-Art Review.量子点在乳腺癌诊断与治疗方式中的适用性——最新综述
Nanomaterials (Basel). 2024 Aug 31;14(17):1424. doi: 10.3390/nano14171424.
8
evaluation of potential breast cancer receptor antagonists from GC-MS and HPLC identified compounds in extracts.通过气相色谱-质谱联用仪(GC-MS)和高效液相色谱仪(HPLC)对潜在乳腺癌受体拮抗剂进行评估,从而鉴定提取物中的化合物。
RSC Adv. 2024 Aug 9;14(33):23744-23771. doi: 10.1039/d4ra03832k. eCollection 2024 Jul 26.
9
Integrating single-cell transcriptomics and machine learning to predict breast cancer prognosis: A study based on natural killer cell-related genes.单细胞转录组学和机器学习整合预测乳腺癌预后:基于自然杀伤细胞相关基因的研究。
J Cell Mol Med. 2024 Aug;28(15):e18549. doi: 10.1111/jcmm.18549.
10
Trim21-mediated CCT2 ubiquitination suppresses malignant progression and promotes CD4T cell activation in breast cancer.Trim21 通过介导 CCT2 泛素化抑制乳腺癌的恶性进展并促进 CD4T 细胞活化。
Cell Death Dis. 2024 Jul 30;15(7):542. doi: 10.1038/s41419-024-06944-8.
Front Oncol. 2022 Aug 8;12:964934. doi: 10.3389/fonc.2022.964934. eCollection 2022.
4
Protein Adsorption Loss─The Bottleneck of Single-Cell Proteomics.蛋白质吸附损失─单细胞蛋白质组学的瓶颈。
J Proteome Res. 2022 Aug 5;21(8):1808-1815. doi: 10.1021/acs.jproteome.2c00317. Epub 2022 Jul 18.
5
High prevalence of somatic PIK3CA and TP53 pathogenic variants in the normal mammary gland tissue of sporadic breast cancer patients revealed by duplex sequencing.双重测序揭示散发性乳腺癌患者正常乳腺组织中体细胞PIK3CA和TP53致病变异的高发生率。
NPJ Breast Cancer. 2022 Jun 29;8(1):76. doi: 10.1038/s41523-022-00443-9.
6
Recent advances in isobaric labeling and applications in quantitative proteomics.近年来同位素质谱标记技术的发展及其在定量蛋白质组学中的应用。
Proteomics. 2022 Oct;22(19-20):e2100256. doi: 10.1002/pmic.202100256. Epub 2022 Jun 22.
7
Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer.基因组分析定义了导管原位癌和复发性浸润性乳腺癌的克隆关系。
Nat Genet. 2022 Jun;54(6):850-860. doi: 10.1038/s41588-022-01082-3. Epub 2022 Jun 9.
8
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial.氟维司群联合卡培他滨对比安慰剂治疗激素受体阳性、HER2 阴性转移性乳腺癌患者在芳香化酶抑制剂治疗复发或进展后的疗效(FAKTION):一项随机、2 期临床试验的总生存、更新的无进展生存和扩展的生物标志物分析。
Lancet Oncol. 2022 Jul;23(7):851-864. doi: 10.1016/S1470-2045(22)00284-4. Epub 2022 Jun 4.
9
Tumour Microenvironment-Immune Cell Interactions Influencing Breast Cancer Heterogeneity and Disease Progression.影响乳腺癌异质性和疾病进展的肿瘤微环境-免疫细胞相互作用
Front Oncol. 2022 May 13;12:876451. doi: 10.3389/fonc.2022.876451. eCollection 2022.
10
Treatment against glucose-dependent cancers through metabolic PFKFB3 targeting of glycolytic flux.通过靶向糖酵解通量的代谢 PFKFB3 治疗葡萄糖依赖性癌症。
Cancer Metastasis Rev. 2022 Jun;41(2):447-458. doi: 10.1007/s10555-022-10027-5. Epub 2022 Apr 14.